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ABSTRACT
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and higher throughput platforms have emerged as
potential tools to advance cardiac drug safety screening. This study evaluated the use of high bandwidth photometry applied to
voltage-sensitive fluorescent dyes (VSDs) to assess drug-induced changes in action potential characteristics of spontaneously
active hiPSC-CM. Human iPSC-CM from 2 commercial sources (Cor.4U and iCell Cardiomyocytes) were stained with the VSD di-4-
ANEPPS and placed in a specialized photometry system that simultaneously monitors 2 wavebands of emitted fluorescence,
allowing ratiometric measurement of membrane voltage. Signals were acquired at 10 kHz and analyzed using custom software.
Action potential duration (APD) values were normally distributed in cardiomyocytes (CMC) from both sources though the mean
and variance differed significantly (APD90: 229615 ms vs 427649 ms [mean6SD, P<0.01]; average spontaneous cycle length:
0.9960.02 s vs 1.476 0.35 s [mean6SD, P<0.01], Cor.4U vs iCell CMC, respectively). The 10–90% rise time of the AP (Trise) was
6 ms and was normally distributed when expressed as 1/T2rise in both cell preparations. Both cell types showed a rate
dependence analogous to that of adult human cardiac cells. Furthermore, nifedipine, ranolazine, and E4031 had similar effects
on cardiomyocyte electrophysiology in both cell types. However, ranolazine and E4031 induced early after depolarization-like
events and high intrinsic firing rates at lower concentrations in iCell CMC. These data show that VSDs provide a minimally
invasive, quantitative, and accurate method to assess hiPSC-CM electrophysiology and detect subtle drug-induced effects for
drug safety screening while highlighting a need to standardize experimental protocols across preparations.
Key words: methods; human induced pluripotent stem cell-derived cardiomyocytes; stem cells; action potential duration;
voltage sensitive dye; drug screening.
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Improving the efficiency of drug development, while minimiz-
ing mid-to-late stage compound attrition, is a continuous focus
of the pharmaceutical industry. A key component of these ef-
forts involves early screening for cardiovascular liabilities,
including delayed ventricular repolarization, a recognized sur-
rogate marker for Torsade de Pointes (TdP) proarrhythmia.
Since 2005, the International Conference on Harmonization’s
(ICH) guideline S7B has driven the preclinical in vitro and
in vivo assays used to assess cardiac liability during the drug
discovery process. This guideline focuses on the potential for
delayed repolarization and includes integrated risk assessments
based on in vitro inhibition of the rapid component of the
delayed inward rectifier (IKr, ie, hERG block) and in vivo QT
measurements (ICH, 2005). Although the S7B guidelines (and
the clinical counterpart E14) have been effective in preventing
the withdrawal of new drugs from the marketplace due to TdP,
the emphasis on screening for IKr current block, without con-
sidering the integrated effects of drugs on the multiple cardiac
currents that define cardiac repolarization and excitability, has
likely led to the unwarranted attrition of novel drug candidates
(De Ponti et al., 2002).
Thus, a group of recognized cardiac safety experts (Cardiac
Safety Research Consortium [CSRC], the Health and
Environmental Sciences Institute [HESI], the US Food and Drug
Administration [FDA] and other key opinion leaders) have pro-
posed a new paradigm to assess the clinical potential for TdP
risk. The group’s proposal, known as the Comprehensive in vitro
Proarrhythmia Assay (CiPA) initiative, provides a multimodal
approach to identifying proarrhythmic risk and takes advantage
of advances in available cell systems and technologies. The
CiPA initiative proposes cardiovascular screening based on
functional responses to multiple cardiac ion channel currents
coupled with in silico reconstructions that model drug effect on
cardiac electrophysiology. These integrated effects are then to
be confirmed through the use of human induced pluripotent
stem cell-derived cardiomyocytes (hiPSC-CM) (Fermini et al.,
2016; Sager et al., 2014), which offer a potential new tool to
examine the effects of compounds on cardiac electrical activity.
Indeed, perforated and whole cell patch clamp techniques have
shown that hiPSC-CM demonstrate individual ionic currents
and overall action potential (Bett et al., 2013) electrophysiology
that are similar to human heart in terms of ionic currents such
as IKr but with reduced expression of other currents (eg, the in-
ward rectifier IK1) (Honda et al., 2011; Jonsson et al., 2012; Ma
et al., 2011).
There are multiple commercial and academic sources of
hiPSC-CM created using differing techniques and source mater-
ials. While their electrophysiology appears superficially similar,
there will be differences in the electrical behavior that may de-
termine the overall response to a drug. Therefore, it is import-
ant to develop techniques that allow routine characterization of
the electrophysiology of different preparations to facilitate com-
parisons across different studies. Various approaches are avail-
able for this task. While considered the “gold standard”
approach, single cell patch clamp electrophysiology is slow and
technically demanding. Extracellular recordings obtained
through multielectrode arrays (MEA) provide a measure of both
the rate of electrical activity and the timing of repolarization,
but lack information regarding morphological changes in the
configuration of the AP and the actual end of repolarization;
changes in both of these parameters are key components to
understanding drug effects. In contrast, transmembrane voltage
signals obtained using voltage-sensing optical techniques pro-
vides an efficient approach to assess the electrophysiological
characteristics of hiPSC-CM at both baseline and following the
addition of drug. Furthermore, voltage-sensitive fluorescent in-
dicators have previously been used to accurately monitor elec-
trical activity in cardiac cells (Dempsey et al., 2016; Klimas et al.,
2016), and this capability offers significant potential when
applied to monitoring electrical activity in hiPSC-CM. This com-
bination of instrument plus indicator offers a robust platform
on which to advance the use of hiPSC-CM within the proposed
guidelines of CiPA.
The aim of the current study was to demonstrate the utility
of the voltage-sensitive dye approach to characterize the base-
line electrophysiology of spontaneously active hiPSC-CM and in
particular determine the sensitivity of the technique to detect
changes in depolarization and repolarization phases of the ac-
tion potential. Using the voltage-sensitive fluorescent indicator
di-4-ANEPPS in a medium/high throughput, multiwell screening
platform (CellOPTIQ), we compared the electrophysiological
characteristics of 2 commercially available hiPSC-CM cell lines,
both of which are thought to represent a stable paradigm of
human-derived cardiomyocytes. Cellular electrophysiology was
assessed under baseline conditions and the relationship be-
tween rate (spontaneous or stimulated) and action potential
duration (APD) was quantified. The effects of 3 drugs with
known cardiac consequences (nifedipine, ranolazine, and
E4031) were assessed across these commercially available cardi-
omyocyte preparations to demonstrate the ability to detect sub-
tle but important differences in electrophysiological responses
using the VSD approach. Our results demonstrate the feasibility
of obtaining high resolution assessments using optical tech-
niques to assess the electrophysiological effects of drugs on
hiPSC-CM during compound discovery and in support of the
CiPA paradigm.
EXPERIMENTAL PROCEDURE
Human induced pluripotent stem cell-derived
cardiomyocyte cell culture
Cryopreserved hiPSC-CM (Cor.4U [Axiogenesis AG, Cologne,
Germany] and iCell Cardiomyocytes [Cellular Dynamics
International, Madison, WI]) were kept in liquid nitrogen until
culture according to the instructions provided by the respective
manufacturers; all studies were conducted using one batch of
cells from either manufacturer. In both cases, the cells were cul-
tured in 96-well glass-bottomed plates (MatTek, Ashland,
Massachusetts) coated with fibronectin (10 mg/ml in PBS supple-
mented with Ca2þand Mg2þ) (Sigma, St. Louis, Missouri) in a
humidified incubator at 37 C for 3h. Cells were plated in ap-
proximately half of the wells for practical convenience and ex-
perimental timing. The cell density for Cor.4U and iCell
Cardiomyocytes (iCell CMC) was 78,000 cells/cm2 (25,000 cells/
well). The subsequent maintenance protocols followed manu-
facturer’s instructions and used the corresponding mainten-
ance media (Cor.4U-maintenance media; iCell Cardiomyocytes
Maintenance media). Experiments were performed between
days 4–8 (Cor.4U) or days 10–15 (iCell CMC) as recommended by
the manufacturers. Prior to beginning an experiment, cells were
washed in serum-free media (SF media), the composition of
which differed for the 2 cells types. Cor.4U cells were exposed to
BMCC media (Axiogenesis); iCell CMC were washed in DMEM
(Gibco, ThermoFisher Scientific, UK) supplemented with 10 mM
galactose and 10mM sodium pyruvate. In both preparations, all
wells showed regularly contracting layers of cells after plating
and waiting the prerequisite number of days. Exclusion criteria
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were based in spontaneous rate limits in that only cells beating
with a cycle length in the range of 0.5–5 s were deemed suitable
for the study; based on these criteria, there were no exclusions
from the study.
Transmembrane potential signals from hiPSC-CM using
voltage sensitive dyes
Both sources of hiPSC-CM were loaded with 6 lM di-4-ANEPPS
(Biotium, Hayward, California) in the above listed SF media for 1
min at room temperature. Cell cultures were then washed in
indicator-free SF media and maintained in an incubator for 2 h
before experimentation. The multiwell plate was placed in the
environmentally controlled stage incubator (37 C, 5% CO2,
water-saturated air atmosphere) (Okolab Inc, Burlingame,
California) of the CellOPTIQ platform (Clyde Biosciences Ltd,
Glasgow, Scotland). The di-4-ANEPPS fluorescence signal was
recorded from a 0.2 mm 0.2 mm area using a 40 (NA 0.6) ob-
jective lens. Excitation wavelength was 4706 10 nm using a
light-emitting diode (LED), and emitted light was collected by 2
photomultipliers (PMTs) at 510–560 nm and 590–650 nm, re-
spectively. LED, PMT, associated power supplies, and amplifiers
were supplied by Cairn Research Ltd (Kent UK). The 2 channels
of fluorescence signals were digitized at 10 kHz, and the ratio of
FIG. 1. Classification of “cellular arrhythmias”. Exemplar records of EAD-like events recorded from hiPSC-CM with distinct characteristics. Type A events are single
transient depolarizations during the plateau phase of the AP. Type B events are oscillating or multiple depolarizing events during the plateau phase. Type C events are
rapid depolarizing events during the late repolarization phase of the AP. Tachycardia-like events are sustained high frequency spontaneous activity (>2 Hz).
FIG. 2. Baseline electrophysiological properties. Baseline action potential properties of Cor.4U cardiomyocytes (n ¼ 168) and iCell Cardiomyocytes (n ¼ 160) using the
voltage-sensitive dye di-4-ANEPPS in combination with the optical platform CellOPTIQ. (A) Representative recordings of spontaneous activity in cellular monolayers in
Cor.4U cells (upper panel) and iCell Cardiomyocytes (lower panel). Averaged APs from each cell population are also shown (right panels). (B) Histograms showing the
distribution of values measured from individual wells from iCell Cardiomyocytes (n ¼ 159) and Cor.4U cardiomyocytes (n ¼ 161) along with the best-fit normal distribu-
tion and the associated mean and standard deviation values for the following parameters: (i) cycle length: iCell Cardiomyocytes ¼ 1.5 6 0.5 s; Cor.4U ¼ 0.99 6 0.14 s.
(ii) APD90: iCell Cardiomyocytes ¼ 427 6 49; Cor.4U ¼ 229 6 15 ms. (iii) diastolic interval: iCell Cardiomyocytes ¼ 1.076 0.44 s; Cor.4U ¼ 0.766 0.13 s.
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fluorescence (short wavelength/long wavelength) was used to
assess the time course of the transmembrane potential inde-
pendent of cell movement (Knisley et al., 2000). The di-4-
ANEPPS staining and AP signals were retained for up to 6 h after
initial treatment.
Drugs were supplied by Sigma Chemical Co. (St Louis,
Missouri) and their identity and concentration were blinded
from the laboratory personnel for the duration of the experi-
ments and subsequent analysis. Baseline spontaneous elec-
trical activity was recorded by capturing a 20 s segment of
fluorescent signal prior to compound addition. Drugs were
tested at 4 concentrations with matched vehicle controls for
each concentration. A 20 s recording was then taken 30 min
after exposure to the drug or vehicle with only one concentra-
tion applied/well. Offline analysis was performed using propri-
etary software (CellOPTIQ). The following (averaged) parameters
were obtained from the AP recordings of 4 independent repli-
cates: cycle length (CL, Hz); rise time (Trise, ms) between 10 and
90% of the AP amplitude, and AP durations (APD, ms) from 10%
to 90% repolarization at 10% intervals.
FIG. 3. Rate dependence of action potential duration. (A) Example AP signals from iCell Cardiomyocytes in response to field stimulation at 0.6, 1, 2, and 3 Hz. (B) Mean
APD90 (6SEM, n ¼ 10) data describing the rate dependence of APD90 based on recordings from Cor.4U (grey points) and iCell (green points) cardiomyocytes in response
to the range of stimulation rates described above. The solid lines through the data are a best-fit single exponential fits to the data: APD ¼ APD0 [1  exp (DI/tau)], where
APD0 is the APD at maximum diastolic interval (DI). (C) Normalization of APD90 values are shown in panel B relative to APDmax at the longest DI. Solid line is the best-fit
exponential: APD ¼ 1  exp(DI/0.12). (D) Relationship between average (6SD) of APD90 and cycle length (CL) during stimulation (solid circles) and during spontaneous
activity (open circles) in Cor.4U cells. The solid line is the best-fit double exponential function: APD90 ¼ APD0 þ A1.exp (CL  CL0)/tau1 þ A2.exp (CL  CL0)/tau2; where
APD0 ¼ 1.28 s, CL0 ¼ 0.007, A1¼1.45, tau1 ¼ 0.0013, A2¼1069, tau2 ¼ 0.021; r2 ¼ 0.93, P < .01. (E) Relationship between average (6SD) of APD90 and CL during stimula-
tion (solid circles) and during spontaneous activity (open circles) in iCell Cardiomyocytes. The solid line is the best-fit double exponential function: APD90 ¼
APD0þA1.exp (CL  CL0)/tau1 þ A2.exp (CL  CL0)/tau2; where APD0 ¼ 0.745, CL0 ¼ 0.780, A1¼0.177, t1 ¼ 0.0007;A2¼404.9, tau2 ¼ 0.0027; r2 ¼ 0.95 P<.01. (F) Average
baseline repolarization profile for the 2 cell types corrected for differences in spontaneous rates (mean6 SD).
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Frequently drugs caused changes in AP shape and spontan-
eous rate that were reminiscent of arrhythmias observed in
whole hearts. For the purposes of discussion, these events are
termed “cellular arrhythmias” to emphasize that they are not
necessarily equivalent to arrhythmic events in the whole heart
since the cellular/sub-cellular basis for these arrhythmia-like
events in 2D cultures of hiPSC-CM is unclear. The observed
trigger-like events recorded in this study were categorized
based on the general waveform shape and timing of the trigger
following the criteria shown in Figure 1. Analysis of cellular ar-
rhythmias consisted of classifying and measuring the incidence
of the early after depolarization-like (EAD) events (Types A, B,
and C). Conversion to rapid spontaneous rates (tachycardia-like
events) or drug-induced quiescence was also recorded.
Field stimulation of hiPSC-CM
In separate experiments to assess the rate dependence of AP
characteristics, cardiomyocytes were field stimulated using
graphite electrodes (15 V, 2 ms pulse  50% above threshold) at
a fixed rate using a MyoPacer (IonOptix Corp, Dublin, Ireland) in
a 35 mm glass-bottomed Petri dish (MatTek). A silicone insert
(Ibidi, Thistle Scientific Ltd, UK) was used within the 35 mm
glass-bottomed Petri dish to minimize the number of cells per
plate.
Data analysis and statistics
Kolmogorov–Smirnov tests were used to determine whether the
data were normally distributed based on a least-squares fit to a
normal function (Origin version 9, OriginLab Corp.,
Northampton, Massachusetts). Statistical analysis was per-
formed using Dunnett’s test following ANOVA to allow the com-
parison of a number of treatments with a single control.
Statistical significance was designated as *P< .05, **P< .01,
***P< .001, ****P< .0001. The relationship between APD90 and CL
or diastolic interval was fit to single or double exponential func-
tions (Origin version 9).
RESULTS
Baseline Electrophysiological Characteristics of Cor.4U
and iCell Cardiomyocytes Obtained Using Voltage-
Sensitive Dyes
Baseline AP tracings from monolayers of spontaneously beating
Cor.4U and iCell CMC are shown in Figure 2A as 9 s segments
of fluorescence ratio signals (left panels) and as the averaged
signals from 20 s recordings (right panels). Figure 2B shows
histograms of data derived from approximately 160 separate 20
s traces of fluorescence ratio recordings from separate wells in
each cell type (n¼ 4 plates of 40 wells/plate). The histograms
of CL values, APD90, and diastolic interval (DI¼CL – APD90) were
fitted with a Gaussian function to illustrate that all 3 param-
eters were normally distributed for both cell types (Fig. 2B).
Cor.4U cells (n¼ 161 wells) exhibited a spontaneous CL of
0.9960.02 s, an APD90 of 2296 15 ms with a CoV of 0.065, and a
DI of 0.766 0.13 s. iCell CMC (n¼ 159 wells) exhibited a CL of
1.4760.35 s, an APD90 of 4276 49 ms with a CoV of 0.166, and a
DI of 1.0760.44 s. When comparing a subgroup of cells from
both cell preparations across a common restricted range of CL
values (0.8–1.2 s), the mean APD values were shorter in the
Cor.4U group (mean APD6SD: 234613 ms, n¼ 62) than the iCell
CMC group (mean APD6SD: 396626 ms, n¼ 22) but the CoV
was similar (SD/mean 0.055 vs 0.066). The same result is ob-
tained when using comparable ranges of DI (data not shown).
None of the AP complexes displayed EAD-like signals or very
high spontaneous rates (>2 Hz) under baseline conditions.
Rate Dependent Changes in APD
The dependence of APD on CL (and DI) was measured across car-
diomyocytes. Figure 3A shows representative fluorescence ratio
recordings from iCell CMC exposed to increasing field stimula-
tion rates of 0.6, 1, 2, and 3 Hz. The relationship between DI and
APD90 across cardiomyocytes is shown in Figure 3B (mean data
and the best fit exponential curve). Figure 3C shows the relation-
ship between APD and DI for hiPSC-CM after normalizing the
APD90 to the maximum value. As shown in Figure 3C, the 2 data
sets show considerable overlap. Over this limited range of DI val-
ues the data could be fit to a single exponential function with a
rate constant (tau) equal to approximately 0.12 s1 (Cor.4U
tau¼ 0.11960.006 s1; iCell CMC tau¼ 0.126 0.012 s1). A com-
parable relationship was observed with APD30 (Cor.4U
tau¼ 0.11860.004 s1; iCell CMC tau¼ 0.1096 0.03 s1) and APD60
FIG. 4. Action potential rise time characteristics. (A) Trise distribution profile
from averaged recordings of di-4-ANEPPS ratio recordings from Cor.4U (n ¼ 168)
and iCell Cardiomyocytes (n ¼ 160). Results expressed as median 6 SD. iCell
Cardiomyocytes ¼ 5.7 6 1.3 ms; Cor.4U ¼ 6.45 6 2.2 ms. Transforming the data to
UVI (1/Trise)
2 results in a normal distribution of the data. Results expressed as
mean 6 SD. iCell Cardiomyocytes ¼ 0.029 6 0.01 ms1; Cor.4U ¼ 0.024 6
0.01 ms1. (B) Indicated mean and standard deviation values are based on the
best fit normal distribution.
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(Cor.4U tau¼ 0.1036 0.022 s1; iCell CMC tau¼ 0.116 0.012 s1).
This data indicates that decreased DI causes a parallel decrease
in APD across the complete repolarization phase of the AP with
sensitivity similar to that observed in adult ventricular cardio-
myocytes (O’Hara et al., 2011).
Figure 3D and E are plots of stimulated and spontaneous val-
ues of APD90 versus CL. The data from spontaneous records
were taken from 100 ms bins across the range of spontaneous
rates. The solid line is the best fit to a double exponential func-
tion for both data sets. This function was subsequently used to
correct all the APD data obtained from hiPSC-CM in this study
to that of a constant CL of 1 s. Correction of the APD90 values to
a CL of 1 s predicted an APD90 of 229613 s for Cor.4U cells and
an APD90 of 3706 30 s for iCell CMC. Using this correction, the
CoV for APD90 was reduced when compared to uncorrected
spontaneous recordings for both Cor.4U and iCell CMC
(CoV¼ 0.056 vs 0.081, Cor.4U vs iCell CMC, respectively). These
relationships were used to correct the complete range of APD
values (10–90%) for the changes in spontaneous CL (see
Supplementary Material online).
The average repolarization profile across cardiomyocytes is
shown in Figure 3F, highlighting the ability of VSDs to detect
subtle differences in AP morphology. The longer APDs observed
in iCell CMC are due to a prolonged plateau phase (phase 2) of
the AP. The curves described by points joined by dotted lines
are the calculated average repolarization values corrected to a 1
s CL based on the relationships described in Figure 3B. After cor-
rection for the different intrinsic rates, the repolarization
time course during AP plateau remained significantly slower
in iCell CMC than in Cor.4U cells. The repolarization profile
of the 2 cell types diverged at 20% of amplitude with Cor.4U
cells repolarizing more rapidly until reaching approximately
70% of amplitude. Terminal repolarization (70–90%) was com-
parable in both cell types. A summary of the baseline AP charac-
teristics is shown in a table in the Supplementary Material
online.
FIG. 5. Effect of nifedipine on action potential characteristics. (A) Example recordings from cells exposed to nifedipine. (B) The average relative (6SD, n ¼ 4) change of
APD50, APD90, and CL in response to nifedipine in Cor.4U cells with values corrected for differences in spontaneous rate. (C) Relative change of APD50, APD90, and CL in
response to nifedipine in iCell Cardiomyocytes with values corrected for differences in spontaneous rate.
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AP Rise Time Characteristics
Figure 4A shows the distribution of AP rise times (Trise) from the
2 cardiomyocyte preparations. Rise time values showed a
skewed (non-normal) distribution about a median value of ap-
proximately 5 ms. Previous work has shown a direct relation-
ship between conduction velocity and (dV/dt)max
2 (Berecki et al.,
2010). Since Trise is inversely related to dV/dt, a more appropri-
ate upstroke velocity index (UVI) is the quantity 1/(T2rise). UVI
was normally distributed in both cell types (Fig. 4B) and showed
similar values for both cell types (0.02460.01 ms2 and
0.02960.09 ms2 for Cor.4U and iCell CMC, respectively).
Effects of Drugs on hiPSC-CM Electrophysiology
The individual records show that the calcium channel blocker
nifedipine (0.01–0.3 lM) caused a dose-dependent shortening of
APD in both cardiomyocyte populations (Fig. 5A). The average
data, expressed as a change in the APD50, APD90, and CL, were
plotted against concentration to show the relative effect of ni-
fedipine on the 2 cell lines. The highest concentration of
nifedipine caused a comparable decrease in APD50 and APD90 in
both groups. Furthermore, nifedipine shortened the CL in both
cell types (Fig. 5B and C, lower panels). However, the effects of
lower concentrations of nifedipine on APD (50 and 90) did not
reach significance in iCell CMC. There were no significant ef-
fects of nifedipine on the upstroke (UVI) of the AP in either cell
type (data not shown).
Next, we examined the effect of the late sodium current inhibi-
tor ranolazine on the AP characteristics. Inhibition of late sodium
current would be expected to shorten the AP, but the individual
records show that increasing concentrations (3–100 lM) of ranola-
zine caused a dose-dependent increase only in APD in both Cor.4U
and iCell CMC (Fig. 6). On average, Cor.4U cells displayed a signifi-
cant dose-dependent lengthening of the AP based on APD50 and
APD90 as well as a lengthening of the CL at 10, 30, and 100 lM
ranolazine (Fig. 6A and B). At higher concentrations, no phases of
rapid intrinsic rate were observed in Cor.4U cells. In iCell CMC, the
response to ranolazine showed a similar trend; 30 lM ranolazine
significantly increased the APD90 (Fig. 6C) and 100 lM inhibited
spontaneous activity in 3 of 4 wells and also caused brief, frequent
FIG. 6. Effect of ranolazine on action potential characteristics. (A) Example recordings from cells exposed to ranolazine. (B) The average relative (6SD, n ¼ 4) change of
APD50, APD90, and CL in response to ranolazine in Cor.4U cells with values corrected for differences in spontaneous rate. (C) Relative change of APD50, APD90, and CL in re-
sponse to ranolazine in iCell Cardiomyocytes with values corrected for differences in spontaneous rate. Note in some instances SD limits were obscured by point size.
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APs (>2 Hz) in the other well (Fig. 6A), these are labeled as “Tachy”
in Figure 6C. There were no significant effects of ranolazine on the
upstroke (UVI) of the AP at concentrations that did not affect in-
trinsic rate (30 lM) (data not shown).
As shown in Figure 7A, the 2 cell types exhibited similar sen-
sitivities towards E4031 at low drug concentrations (0.003 and
0.01 lM), which, on average, significantly prolonged APD90 to
approximately 150 and 200% of control values in Cor.4U and
iCell CMC, respectively (Fig. 7B and C). At higher concentrations
(0.03 and 0.1 lM), iCell CMC exhibited EAD-like events (ie, sec-
ondary depolarizing events during the plateau phase of the AP).
In one well, the drug caused a sustained increase in rate to
above 2 Hz. EAD-like events were observed in Cor.4U cells only
at the highest concentration (0.1 lM) of E4031. There were no
significant effects of E4031 on the upstroke (UVI) of the AP (data
not shown) or induction of quiescence of spontaneous rate in
either iCELL CMC or Cor.4U cells.
Figure 8 summarizes all 3 drug responses for the 2 cell types
by displaying the average repolarization profiles corrected to a 1
s CL assuming the drugs have no marked rate dependence to
their action (see Supplementary Material online). The diagram
illustrates that, despite differences in their initial repolarization
profile, the overall effects of the drugs were similar in both cell
lines. Nifedipine shortened all phases of repolarization to a
similar extent, while ranolazine and E4031 prolonged the late
phase of the AP with the involvement of EAD-like behavior, gen-
erating voltage transients that started during the AP plateau.
A summary of the arrhythmia-like events and rate changes de-
veloped by the 2 cell types in response to ranolazine and E4031
is shown in Figure 9. A range of EAD-like behavior was observed
and categorized into 2 types of responses: “type A” EADs are sin-
gle rapid depolarizing events during phase 2 (plateau) of the AP,
and “type C” EADs are a rapid depolarization late in the repolari-
zation phase (phase 3). Since arrhythmic events did not occur at
each AP, the percentage of APs with EAD-like events was plot-
ted. Furthermore, some traces displayed both type A and type C
complexes. Abrupt increases in the intrinsic rate to>2 Hz also
occurred as an arrhythmic-like event in hiPSC-CM; these events
were labeled as “Tachy”, and examples are shown in Figure 9A
for both drugs. Figure 9B compares the relative incidence of
both types of arrhythmic events for ranolazine and E4031. Type
A and Tachy arrhythmias were evident in iCell CMC at 30 lM
ranolazine, while the cells were either electrically quiescent or
displaying a high intrinsic rate of APs (Tachy) at 100 lM.
FIG. 7. Effect of E4031 on action potential characteristics. (A) Example recordings from cells exposed to E4031. (B) The average relative (6SD, n ¼ 4) change of APD50,
APD90, and CL in response to E4031 in Cor.4U cells with values corrected for differences in spontaneous rate. (C) Relative change of APD50, APD90, and CL in response to
E4031 in iCell Cardiomyocytes with values corrected for differences in spontaneous rate. Note in some instances SD limits are obscured by point size.
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Ranolazine did not elicit cellular arrhythmias in Cor.4U cells
even at the highest concentration tested (100 lM). E4031 elicited
EAD-like events in some wells of iCell CMC at 10 nM and with a
higher incidence at 30 nM. With 100 nM E4031, iCell CMC dis-
played Tachy-like behavior and 2 forms of EAD behavior (Type
A & C, Fig. 1). In contrast, Cor.4U cells displayed EAD-like and
Tachy-like behavior only at 100 nM E4031. The rise time of the
AP was not significantly altered by any drug used in this study
at concentrations that did not display EAD-like or Tachy-like
arrhythmias.
DISCUSSION
This study examines the use of the VSD di-4-ANEPPS to record
changes in the membrane potential of hiPSC-CM from
2 commercial sources. The data demonstrate the feasibility of
high bandwidth photometry applied to a multiwell plate format
for reporting cellular electrical activity of cultured cardiomyo-
cytes and for detecting drug-induced changes in cardiomyocyte
electrophysiology. Furthermore, the data show that the VSD
technology is sensitive and robust enough to quantify differ-
ences pre- and post-drug application. The subsequent analysis
provides additional details on varying types of cellular arrhyth-
mias, describes techniques for optimizing assay sensitivity, and
underscores the utility of detecting changes in ventricular repo-
larization and depolarization.
Whereas the di-4-ANEPPS signals recorded from Cor.4U and
iCell CMC exhibited distinct electrophysiological characteristics,
the APD and CL values recorded from different culture wells
were similar and showed a variability that was normally distrib-
uted in both cell types. The mean APD and spontaneous CL val-
ues (and associated coefficients of variation [CoV]) recorded in
iCell CMC were significantly greater than those of Cor.4U cells
whereas the time for the AP upstroke was similar in both cell
types. The explanation for the difference in the mean APD and
CL between the 2 cell types is unknown but may be due to:
(i) differences in the type, magnitude, and kinetics of the ionic
conductances present in the dominant cardiomyocyte subtypes
between the 2 cell lines (Paci et al., 2013); (ii) differences in the
range of cell types within the culture (Bett et al., 2013; Du et al.,
2015; Scheel et al., 2014); and (iii) differences in the composition
of the incubation medium. As data do not exist to allow for
comparison between iCell CMC and Cor.4U cells for these par-
ameters, the differences between the electrophysiological
phenotypes (including differences in the AP plateau) is unclear
and the potential difference in the range of cardiac cell types
in the 2 sources cannot be determined. In addition, the current
studies were conducted using different proprietary incubation
media as recommended by the respective manufacturers. Since
the composition of these solutions is not published, small dif-
ferences in extracellular potassium, sodium, magnesium, and
calcium ions, pH, or glucose may contribute to the observed dif-
ferences in APD and CL. Thus, quantifying the relationship be-
tween APD parameters and CL would allow correction for
changes purely associated with rate caused either by altered
baseline rate or by drug-induced changes and, therefore, would
improve the ability to resolve changes in mean APD.
The rate dependence of APD90 approximates to an exponen-
tial decay when examined at DI values less than 1 s. The APD90
measurements for iCell CMC (370 ms) and Cor.4U cells (220 ms)
at the longer DI values do not approximate the APD90 value re-
ported for human ventricle (300 ms) (O’Hara et al., 2011). Despite
this difference between hiPSC-CM and adult ventricle in max-
imum APD90, the shape of the rate dependence of APD was
similar (Fig. 3C), suggesting that although maximum APD values
in both cell types are different from adult human cardiac cells,
the relative sensitivity of the time-dependent processes under-
lying the rate dependence of the APD are similar. The variation
of APD with CL in both stimulated and spontaneously active
cells across a large range of CL values allowed the development
of a rate correction formula that applied across a wide range of
CLs. After correction, the CoV of APD90 was reduced for both
Cor.4U and iCell CMC when compared to uncorrected spontan-
eous recordings; after rate correction, iCell CMC CoV was com-
parable to Cor.4U cells (0.08 vs 0.05).
When assessing the utility of VSDs to quantify drug-induced
changes in cardiomyocyte electrophysiology, Cor.4U and iCell
CMC demonstrated the expected responses to 3 cardio-active
FIG. 8. Repolarization profiles (nifedipine, ranolazine, and E4031). Average rate
corrected repolarization profiles for Cor.4U and iCell Cardiomyocytes in re-
sponse to increasing concentrations of (i) nifedipine, (ii) ranolazine, and (iii)
E4031 (mean 6 SD, n ¼ 4).
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compounds. The L-type calcium channel (ICa,L) blocker nifedi-
pine caused dose-dependent shortening of the APD and a
decrease in the intrinsic CL. Therefore, these data reflect the
well-established effect of shortening of the ventricular APD in
response to ICa,L block that is seen across multiple mammalian
species (Coraboeuf and Nargeot, 1993) and in hiPSC-CM (Peng
et al., 2010) as well as the ability of VSDs to detect and quantify
such changes. The relative effects on APD at equivalent concen-
trations of the drug were comparable in both cell types.
Furthermore, the IC50 of nifedipine to the isolated channel is
0.2–0.3 lM (Peng et al., 2010), which is comparable to the max-
imum concentration used in the study. Indeed, 0.3 lM nifedi-
pine shortened APD90 to approximately 50% of control values in
both cell types. This sensitivity is also in line with estimates of
the effective therapeutic plasma concentration (ETPC) of nifedi-
pine (3–8 nM) (Redfern et al., 2003).
Ranolazine blocks the late sodium current [INa(late)] with an
IC50 of 7 lM in a heterologously expressed human LQT3 mutant
sodium channel system (Rajamani et al., 2009) and an IC50 of 6.5
lM in failing isolated canine ventricular myocytes (Undrovinas
et al., 2006). Higher ranolazine concentrations inhibit the rapidly
inactivating potassium conductance (IKr), ICa,L, and the slowly
inactivating potassium conductance (IKs) (Schram et al., 2004;
Song et al., 2004). In vitro, ranolazine does not affect the APD of
dog or human ventricular papillary muscles while it signifi-
cantly shortened APD in canine Purkinje fibers (Szel et al., 2011).
Clinically, ranolazine slightly prolongs the QT interval in
healthy subjects (Vicente et al., 2015) and in patients with an-
gina (Chaitman, 2004). Therefore, while inhibition of INa(late)
alone would be expected to shorten APD, neither cardiomyocyte
preparation we studied showed APD shortening at the approxi-
mate ETPC (0.6–5 lM) (Lu et al., 2015), which is qualitatively con-
sistent with clinical ECG findings. It is possible that the less
polarized resting membrane potentials of hiPSC-CM (compared
to adult heart) leads to inactivation of a significant amount of
both early and late INa components, potentially minimizing the
magnitude of INa(late) during the plateau. The mechanisms re-
sponsible for the complex cellular proarrhythmia observed with
some myocytes at supratherapeutic exposures of ranolazine are
unclear.
FIG. 9. Incidence of cellular arrhythmias (Ranolazine and E4031). Summary of the presence, incidence, and type of cellular arrhythmias observed in Cor.4U and iCell
Cardiomyocytes following ranolazine and E4031. (A) Presence and type of cellular arrhythmia (with exemplars). (B) Plot of drug concentration versus incidence of cellu-
lar arrhythmia with each point representing incidence in 20 s recording from a single well.
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The selective IKr blocker E4031 appeared to have qualita-
tively similar effects on the APD in iCell CMC and Cor.4U cells.
As with ranolazine, VSDs were able to distinguish between mul-
tiple EAD-like events, which were evident at lower concentra-
tions of E4031 in iCell CMC. The IC50 for block of IKr (current) by
E4031 is approximately 10 nM (Zhou et al., 1998), the concentra-
tion that elicits APD prolongation to approximately140% of con-
trol in both cell types in this study.
In summary, both Cor.4U and iCell CMC showed similar re-
sponses to each drug: the relative effects of nidefipine on
APD10–90% are similar despite the differences in baseline APD;
ICa,L block caused a shortening of APD from the earliest phase
(phase 2) of repolarization; and IKr inhibition with either ranola-
zine or E4031 prolonged APD in the late phase of repolarization,
consistent with the role of IKr in phase 3 repolarization in the
adult ventricular myocyte (Gintant, 2000). Both cardiomyocyte
populations showed cellular arrhythmias in the presence of
hERG channel blockers; the high variability of the late repolari-
zation phase in these recordings, particularly from iCell CMC,
was caused by the presence of AP complexes with variable and
prolonged plateau phases without overt EADs. These data re-
flect similar results reported both in adult hearts (Thomsen
et al., 2006) and hiPSC-CM (Jonsson et al., 2010), showing that in-
hibition of IKr under conditions of a longer APD generates a
higher incidence of arrhythmic events, although this has yet to
be systematically studied in hiPSC-CM. EAD-like events
occurred across cardiomyocytes when APD90 values exceeded
approximately 500 ms. These APD90 values were observed only
at the highest concentrations of ranolazine and E4031 in Cor.4U
cells whereas an APD90 of greater than 500 ms was achieved at
considerably lower concentrations of ranolazine and E4031 in
iCell CMC. The differences in drug response in the 2 hiPSC-CM
sources are comparable to differences observed in heart cells
from different small animal models and highlight the need to
calibrate electrophysiological responses with known standards.
Further, these observed differences in responses are useful to
define assay sensitivity and place results in context of clinical
findings and do not reflect on the utility of either myocyte
preparation.
These results demonstrate that the VSD platform offers an
alternative to glass microelectrode and MEA techniques in the
detection of cardiotoxic effects and testing of novel lead com-
pounds (Kraushaar et al., 2012). They further demonstrate that
quantitative differences exist between hiPSC-CMs from differ-
ent sources and that resulting data must be interpreted and
benchmarked in accordance with the characteristics of a par-
ticular cell source. The VSD approach is similar to glass micro-
electrode studies in that it provides details on effects
throughout repolarization as manifest by changes in morph-
ology of the AP (eg, APD30, APD60, and APD90) (Peng et al., 2010;
Scheel et al., 2014) and APD triangulation, a recognized hallmark
of proarrhythmia (Hondeghem, 1994); thus, providing a more
detailed assessment of repolarization instability as compared to
MEA techniques. Furthermore, being able to resolve the plateau
phase directly in VSD signals makes detection and identifica-
tion of EAD-like events easier than with MEA signals, which
adds value in assessing proarrhythmic liabilities in the evolving
CiPA paradigm. Overall, the simplicity of optical measurements
with VSDs provides a medium-to-high throughput technology
that allows for the use of hiPSC-CM to aid in drug discovery and
improves early detection of potential cardiac liability in com-
pound development.
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